Shuangdeng Group Reshuffles Corporate Secretarial Roles; Secures Three-Year HKEX Waiver for New Joint Company Secretary

Shuangdeng Group Co., Ltd. (Shuangdeng) announced a leadership transition in its corporate secretarial team effective 15 June 2026.

Executive Director and Chief Financial Officer He Rong will step down as Board Secretary, Joint Company Secretary and Authorised Representative. She remains on the Board and retains her CFO position. He Rong confirmed there is no disagreement with the Board and no issues requiring shareholder or Stock Exchange attention.

Ma Yunpeng Moses, currently Director of Shuangdeng’s Investment and Securities Department, will assume the roles vacated by He Rong. Ma brings 13 years of finance-market experience, including senior positions at Capella Capital, Zhongtai International Asset Management, Taiping Asset Management (HK) and Harvest Global Investment. He holds a bachelor’s degree in economics and finance from the University of Hong Kong.

Tam Ka Lung, a fellow of the Association of Chartered Certified Accountants and member of the Hong Kong Institute of Certified Public Accountants, continues as the other Joint Company Secretary. Tam has over 20 years’ experience in auditing, financial management, corporate governance and capital-markets transactions.

Because Ma does not yet meet the professional qualification requirements for company secretaries under Hong Kong Listing Rules 3.28 and 8.17, Shuangdeng obtained a three-year waiver from the Stock Exchange. The waiver is conditional on:

1. Ma receiving ongoing support from Tam throughout the waiver period. 2. Absence of material Listing Rule breaches by the company.

Before the waiver expires, Shuangdeng must demonstrate to the Stock Exchange that Ma has gained sufficient experience to discharge company-secretary duties independently.

The Board expressed gratitude to He Rong for her service and formally welcomed Ma to his new positions.

As of the announcement date, Shuangdeng’s Board comprises three executive directors (Dr. Yang Rui, Dr. Yang Baofeng, He Rong), three non-executive directors (Qian Shan’gao, Lou Zhiqiang, Hu Shuxuan) and three independent non-executive directors (Dr. Yin Junming, Dr. Wang Jin, Dr. Wang Xi).